Arvinas Holding Company (ARVN) has issued an update.
Arvinas, Inc. has appointed Dr. Noah Berkowitz as its new chief medical officer to spearhead the clinical development of its innovative PROTAC® protein degrader programs in the fields of oncology and neuroscience. With a solid track record of over 20 years in the pharmaceutical industry, Dr. Berkowitz brings valuable experience from his previous leadership role in hematology at Bristol-Myers Squibb. Concurrently, the company is preparing for a smooth transition as Dr. Ron Peck, the former chief medical officer, will remain on board until mid-April 2024 to assist with the handover before he departs to explore new ventures.
Find detailed analytics on ARVN stock on TipRanks’ Stock Analysis page.
